Drug intelligence / Profile preview

voxilaprevir

Development stage: Phase 4
Lead developer: Gilead Sciences
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Voxilaprevir is a direct-acting antiviral (DAA) medication used as part of combination therapy to treat chronic hepatitis C virus (HCV) infection. It is an inhibitor of the HCV NS3/4A serine protease, which is essential for viral replication. By inhibiting this protease, voxilaprevir prevents the cleavage of viral polyproteins into functional proteins required for assembly and replication of the virus. Voxilaprevir is not used alone but in combination with sofosbuvir and velpatasvir (marketed as Vosevi), particularly in adults who have previously received other HCV treatments.

Brand names: Vosevi
Other names: VOX

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)

Beyond the preview

Go deeper on voxilaprevir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on voxilaprevir.

Explore the full profile